Get started
Award

11650

Funded outputs count: 100
Funder award ID: 11650
OpenAlex ID: G6591838237
Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial
2024 · James Larkin, Richard Marais, et al. · Cell Reports Medicine · 20
PDF
Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT
2024 · Richard S. Finn, Shukui Qin, et al. · Liver Cancer · 9
Impact of the COVID-19 pandemic on patients with hepatocellular carcinoma in the West of Scotland: a cohort study
2023 · Alistair Stewart McLaren, Johannes A Spoor, et al. · BMJ Open Gastroenterology · 2
PDF
Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance
2023 · Christina Yap, Jan Rekowski, et al. · BMJ · 29
PDF
Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance
2023 · Christina Yap, Olga Solovyeva, et al. · BMJ · 52
PDF
Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE study
2023 · Olga Solovyeva, Munyaradzi Dimairo, et al. · BMC Medicine · 13
PDF
Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study
2023 · Omid Hamid, Jessica C Hassel, et al. · Journal for ImmunoTherapy of Cancer · 33
PDF
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer
2023 · Rebecca Kristeleit, Ruth Plummer, et al. · British Journal of Cancer · 40
PDF
Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study
2023 · Matthew G. Krebs, Jean-Pierre Delord, et al. · Lung Cancer · 42
PDF
SPIRIT and CONSORT extensions for early phase dose-finding clinical trials: the DEFINE (DosE-FIndiNg Extensions) study protocol
2023 · Aude Espinasse, Olga Solovyeva, et al. · BMJ Open · 24
PDF
Liquid Biopsy for Pancreatic Cancer Detection Using Infrared Spectroscopy
2022 · Alexandra Sala, James M. Cameron, et al. · Cancers · 34
PDF
Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies
2022 · Robert J. Motzer, Matthew H. Taylor, et al. · Expert Review of Anticancer Therapy · 65
Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors
2022 · Claire Glen, Yun Yi Tan, et al. · JACC CardioOncology · 75
PDF
The need for reporting guidelines for early phase dose-finding trials: Dose-Finding CONSORT Extension
2022 · Christina Yap, Alun Bedding, et al. · Nature Medicine · 32
Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer
2021 · Ayumi Hashimoto, Debashis Sarker, et al. · Clinical Cancer Research · 97
Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study
2021 · Richard S. Finn, Masatoshi Kudo, et al. · Clinical Cancer Research · 79
PDF
Quantitative Multiplex Immunofluorescence Evaluation of the Tumor Microenvironment in Pretreatment Tumors of Patients with Metastatic Breast Cancer and Serous Ovarian Carcinoma Treated with Liposomal Eribulin
2021 · Douglas K. Marks, John Kucharczyk, et al. · Cancer Investigation
Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours
2021 · Mark R. Middleton, Emma Dean, et al. · British Journal of Cancer · 126
PDF
Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer
2021 · Ming Lei, Nathan O. Siemers, et al. · Clinical Cancer Research · 90
PDF
A monolithic single-chip point-of-care platform for metabolomic prostate cancer detection
2021 · Valerio F. Annese, Samadhan B. Patil, et al. · Microsystems & Nanoengineering · 35
PDF
Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma
2019 · Angel Alsina, Masatoshi Kudo, et al. · Liver Cancer · 76
PDF
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours
2019 · Robin L. Jones, Mark J. Ratain, et al. · European Journal of Cancer · 29
PDF
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial
2019 · R. Wendel Naumann, Antoine Hollebecque, et al. · Journal of Clinical Oncology · 440
The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy
2019 · Claire S Reader, Sabari Vallath, et al. · The Journal of Pathology · 115
PDF
Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma
2019 · Thomas R. Jeffry Evans, Masatoshi Kudo, et al. · British Journal of Cancer · 28
PDF
Year
Topic